Menu
Search
|

Menu

Close
X

CASI Pharmaceuticals Inc CASI.OQ (NASDAQ Stock Exchange Capital Market)

3.52 USD
+0.19 (+5.71%)
As of Nov 15
chart
Previous Close 3.33
Open 3.28
Volume 44,180
3m Avg Volume 96,115
Today’s High 3.55
Today’s Low 3.28
52 Week High 8.88
52 Week Low 2.42
Shares Outstanding (mil) 60.20
Market Capitalization (mil) 113.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.219
FY17
-0.172
FY16
-0.185
FY15
-0.222
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
6.65
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
8.78
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
-45.17
14.22
Return on Equity (TTM)
vs sector
-62.67
15.99

EXECUTIVE LEADERSHIP

Wei-Wu He
Executive Chairman of the Board, Since 2018
Salary: --
Bonus: --
Ken Ren
Chief Executive Officer, Director, Since 2014
Salary: $389,375.00
Bonus: $370,000.00
George Chi
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Cynthia Hu
Chief Operating Officer, General Counsel, Secretary, Since 2008
Salary: $329,167.00
Bonus: --
Sara Capitelli
Vice President - Finance, Principal Accounting Officer, Since 2011
Salary: $175,100.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9620 Medical Center Dr Ste 300
ROCKVILLE   MD   20850-3396

Phone: +1240.8642600

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

SPONSORED STORIES